(R)-(-)-N-tritylprolinamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 三苯基化合物
• 英文名称: (R)-(-)-N-tritylprolinamide
• 英文别名: 1-[(2R)-1-Tritylpyrrolidin-2-yl]methanamine；[(2R)-1-tritylpyrrolidin-2-yl]methanamine
• 化学式: C₂₄H₂₆N₂
• 分子量: 342.484
• InChiKey: URSGFPXAORJLCF-HSZRJFAPSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  26
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  29.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (R)-(-)-N-tritylprolinamide 在 盐酸 、 氯甲酸乙酯 、 三乙胺 作用下， 以 乙醇 为溶剂， 反应 4.5h， 生成 (R)-(-)-2,3-dimethoxy-5-iodo-N-(2-pyrrolidinylmethyl)benzamide
  参考文献：
  名称：

  Fluorinated and iodinated dopamine agents: D2 imaging agents for PET and SPECT

  摘要：

  A novel series of dual-labeling D2 dopamine agents (labeled with either F-18 or I-123 for PET or SPECT imaging, respectively) was investigated. Two desired fluorinated and iodinated dopamine agents, FIDA1, (S)-(-)-2-(2-fluoroethoxy)-5-iodo-3-methoxy-N-[(1-ethyl-2-pyrrolidinyl)methyl]benzamide, and FIDA2, (R)-(+)-2,3-dimethoxy-5-iodo-N-[(1-(4'-fluorobenzyl)-2-pyrrolidinyl)methyl]benzamide, were synthesized. Both compounds displayed high affinity to the D2 receptor of rat striatal membrane preparations (K(d) = 0.13 and 0.02 nM for FIDA1 and FIDA2, respectively). The biodistribution study in rats exhibited high localization in the striata of the brain with the striatum/cerebellum ratio reaching 29.3 and 13.1 at 1 h post iv injection for FIDA1 and FIDA2, respectively. Imaging studies with [F-18]- and [I-123]FIDA2 in monkeys, with PET and SPECT, respectively, showed comparable high selective striatal uptake. These results suggest that they are potentially useful D2 dopamine receptor imaging agents for PET and SPECT.

  DOI：

  10.1021/jm00054a005
• 作为产物：
  描述：

  D-脯氨酰胺 在 sodium tetrahydroborate 作用下， 以 1,4-二氧六环 、 溶剂黄146 为溶剂， 生成 (R)-(-)-N-tritylprolinamide
  参考文献：
  名称：

  Fluorinated and iodinated dopamine agents: D2 imaging agents for PET and SPECT

  摘要：

  A novel series of dual-labeling D2 dopamine agents (labeled with either F-18 or I-123 for PET or SPECT imaging, respectively) was investigated. Two desired fluorinated and iodinated dopamine agents, FIDA1, (S)-(-)-2-(2-fluoroethoxy)-5-iodo-3-methoxy-N-[(1-ethyl-2-pyrrolidinyl)methyl]benzamide, and FIDA2, (R)-(+)-2,3-dimethoxy-5-iodo-N-[(1-(4'-fluorobenzyl)-2-pyrrolidinyl)methyl]benzamide, were synthesized. Both compounds displayed high affinity to the D2 receptor of rat striatal membrane preparations (K(d) = 0.13 and 0.02 nM for FIDA1 and FIDA2, respectively). The biodistribution study in rats exhibited high localization in the striata of the brain with the striatum/cerebellum ratio reaching 29.3 and 13.1 at 1 h post iv injection for FIDA1 and FIDA2, respectively. Imaging studies with [F-18]- and [I-123]FIDA2 in monkeys, with PET and SPECT, respectively, showed comparable high selective striatal uptake. These results suggest that they are potentially useful D2 dopamine receptor imaging agents for PET and SPECT.

  DOI：

  10.1021/jm00054a005

文献信息

• PYRIDINOPYRIDINONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF
  申请人：BELLEVERGUE Patrice

  公开号：US20110124643A1

  公开（公告）日：2011-05-26

  The present invention relates to pyridopyridone derivatives of formula (I): in which the variables are as defined herein, to their preparation and to their therapeutic use as inhibitors of the kinase activity of PDGF (platelet-derived growth factor) ligand receptors and possibly of FLT3 (fms-like tyrosine kinase receptor) ligand receptors.

  本发明涉及公式（I）的吡啶吡啶酮衍生物，其中变量如本文所定义，涉及其制备以及作为PDGF（血小板源性生长因子）配体受体激酶活性抑制剂以及可能的FLT3（类似Fms酪氨酸激酶受体）配体受体的治疗用途。
• Pyridinopyridinone derivatives, preparation thereof and therapeutic use thereof
  申请人：Bellevergue Patrice

  公开号：US08436011B2

  公开（公告）日：2013-05-07

  The present invention relates to pyridopyridone derivatives of formula (I): in which the variables are as defined herein, to their preparation and to their therapeutic use as inhibitors of the kinase activity of PDGF (platelet-derived growth factor) ligand receptors and possibly of FLT3 (fms-like tyrosine kinase receptor) ligand receptors.

  本发明涉及式(I)的吡啶吡酮衍生物，其中变量如此定义，以及它们的制备和作为PDGF（血小板源性生长因子）配体受体和可能的FLT3（fms-类酪氨酸激酶受体）配体受体激酶活性抑制剂的治疗用途。
• DERIVES DE PYRIDINO-PYRIDINONES, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE
  申请人：Sanofi-Aventis

  公开号：EP2315767A2

  公开（公告）日：2011-05-04
• US8436011B2
  申请人：——

  公开号：US8436011B2

  公开（公告）日：2013-05-07
• [EN] PYRIDINO-PYRIDINONE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF<br/>[FR] DERIVES DE PYRIDINO-PYRIDINONES, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE
  申请人：SANOFI AVENTIS

  公开号：WO2010004197A2

  公开（公告）日：2010-01-14

  L'invention concerne les dérivés de pyridino-pyridinones, de formule générale (I): dans laquelle R1, R2, R3, R4, R5, R6, R7, V, W, Y, Z, m sont tels que définis dans la description. Procédé de préparation et application en thérapeutique.